Istically significant period effect was found (P values i0.52). The primary statistical analysis gave an estimate of the reduction in saquinavir exposure when coadministered with rifabutin, as measured by AUC(0,8 h) and Cmax(0,8 h) of 47 (95 CI 30, 60 ) and 39 (95 CI 11, 59 ), respectively. Figure 1 illustrates the plasma concentrationtime profiles for saquinavir when administered alone (Treat